Clinical Trials

Untreated Mantle Cell Lymphoma:

2012-0293	A Phase 1b Study Combining Ibrutinib with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects with CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL)
2006-0697	Bortezomib + R-HyperCVAD alternating with Bortezomib + R-High dose Methotrexate/Cytarabine in Untreated Aggressive Mantle Cell Lymphoma

2012-0377	A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy
2009-0057	Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed/refractory Mantle Cell Lymphoma
2010-0261	Phase II Study of MK-2206 in Patients with Relapsed Lymphoma
2012-0137	A Phase 1 Study of IPI-145 in Patients with Advanced Hematologic Malignancies